title: Traumatic brain injury in mice and pentadecapeptide BPC 157 effect.
abstract: Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. After an induced traumatic brain injury (TBI) in mice by a falling weight, BPC 157 regimens (10.0microg, 10.0ng/kgi.p.) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24h post-injury period. Ultimately, the traumatic lesions (subarachnoidal and intraventricular haemorrhage, brain laceration, haemorrhagic laceration) were less intense and consecutive brain edema had considerably improved. Given prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-mice was after force impulses of 0.068 Ns, 0.093 Ns, 0.113 Ns, 0.130 Ns, 0.145 Ns, and 0.159 Ns. Counteraction (with a reduction of unconsciousness, lower mortality) with both microg- and ng-regimens included the force impulses of 0.068-0.145 Ns. A higher regimen presented effectiveness also against the maximal force impulse (0.159 Ns). Furthermore, BPC 157 application immediately prior to injury was beneficial in mice subjected to force impulses of 0.093 Ns-TBI. For a more severe force impulse (0.130 Ns, 0.145 Ns, or 0159 Ns), the time-relation to improve the conscious/unconscious/death ratio was: 5 min (0.130 Ns-TBI), 20 min (0.145 Ns-TBI) or 30 min (0.159 Ns-TBI).
authors.affiliation: Department of Pharmacology, Medical Faculty University of Zagreb, 10000 Zagreb, Croatia.
authors.forename: Mario
authors.initials: M
authors.lastname: Tudor
authors.forename: Ivan
authors.initials: I
authors.lastname: Jandric
authors.forename: Anton
authors.initials: A
authors.lastname: Marovic
authors.forename: Miroslav
authors.initials: M
authors.lastname: Gjurasin
authors.forename: Darko
authors.initials: D
authors.lastname: Perovic
authors.forename: Bozo
authors.initials: B
authors.lastname: Radic
authors.forename: Alenka Boban
authors.initials: AB
authors.lastname: Blagaic
authors.forename: Danijela
authors.initials: D
authors.lastname: Kolenc
authors.forename: Luka
authors.initials: L
authors.lastname: Brcic
authors.forename: Kamelija
authors.initials: K
authors.lastname: Zarkovic
authors.forename: Sven
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Predrag
authors.initials: P
authors.lastname: Sikiric
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects*; D001930:Brain Injuries / Q000188:drug therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010446:Peptide Fragments / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157